表观扩散系数图与Kaiser评分在乳腺病变评估中的多中心比较
这项多中心研究分析了3个中心414例患者共450个经组织学证实的乳腺病变,由2名经验丰富的放射科医师回顾性共识判读并应用Kaiser评分(KS),同时测量病变平均ADC并计算KS+评分。KS的AUROC为0.915,显著优于ADC的0.848(P<0.001),在小于1 cm病变中差异最大;KS+较单用KS或ADC略有提升但无显著差异。在避免不必要活检方面,KS与ADC敏感度均为97.7%,但KS特异度65.4%高于ADC的32.9%(P<0.0001)。
要点
- KS鉴别乳腺良恶性病变的AUROC为0.915,显著优于ADC的0.848(P<0.001)。
- 评估小于1 cm病变时KS的AUROC为0.909,优于ADC的0.811(P=0.02)。
- 高敏感度阈值下KS与ADC敏感度均为97.7%,但KS特异度65.4%高于ADC的32.9%。
核心结论
- KS与ADC均可用于区分乳腺良恶性病变,但KS在该任务中表现更优,尤其是在评估小于1 cm的小病变时。
- 使用KS可能避免的不必要活检数量约为ADC的两倍,而KS与ADC联合(KS+)并未提升诊断性能。
研究设计与样本
- 多中心研究,分析来自3个中心的个体患者数据。
- 纳入因标准非筛查适应证接受标准化多参数乳腺MRI的连续患者。
- 共纳入414例患者的450个组织学证实的病变,患者平均年龄51.5岁(四分位距42–60.8岁)。
- 各中心由2名经验超过5年的放射科医师回顾性共识判读,对每个病变应用KS,并用Wielema 4型感兴趣区测量平均ADC,按既定方法组合为KS+评分。
- 以AUROC评价诊断准确性(DeLong检验比较KS、ADC与KS+),并基于既定高敏感度阈值比较避免不必要活检的潜力(McNemar检验)。
关键影像表现/征象
- 450个病变中219个为恶性(48.7%;95%CI 44%–53.4%)。
诊断标准与关键数值
- KS的AUROC为0.915(95%CI 0.886–0.939),显著优于ADC的AUROC 0.848(95%CI 0.811–0.880;P<0.001)。
- 评估小于1 cm病变时,KS的AUROC为0.909(95%CI 0.849–0.950),ADC为0.811(95%CI 0.737–0.871),P=0.02。
- KS+的AUROC为0.918(95%CI 0.889–0.942),较单用KS或ADC略有提升但无显著差异(P=0.64)。
- 应用高敏感度阈值避免不必要活检时,KS与ADC敏感度均为97.7%,截断值分别为KS>4、ADC≤1.4×10⁻³ mm²/s。
- 避免不必要活检的比例KS高于ADC(特异度:KS 65.4% vs ADC 32.9%;P<0.0001),且KS在避免不必要活检方面优于KS+。
临床应用与阅片要点
- KS和ADC均可用于乳腺MRI病变的良恶性鉴别,阅片时可结合KS评分与ADC测量。
- 评估小于1 cm的小病变时KS优势更明显,ADC判读需注意其在该类病变中的表现。
- 采用高敏感度阈值时,KS与ADC均保持97.7%的敏感度,但KS可避免更多不必要活检(特异度65.4% vs 32.9%)。
- KS与ADC联合(KS+)未带来显著诊断性能提升,作者认为KS与ADC联合不改善诊断性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
MATERIALS AND METHODS: In this multicentric study, individual patient data from 3 different centers were analyzed. Consecutive patients receiving standardized multiparametric breast magnetic resonance imaging for standard nonscreening indications were included. At each center, 2 experienced radiologists with more than 5 years of experience retrospectively interpreted the examinations in consensus and applied the KS to every histologically verified lesion. The corresponding mean ADC of each lesion was measured using a Wielema type 4 region of interest. According to established methods, the KS and ADC were combined, yielding the KS+ score. Diagnostic accuracy was evaluated by the area under the receiver operating characteristics curve (AUROC) and compared between the KS, ADC, and KS+ (DeLong test). Likewise, the potential to help avoid unnecessary biopsies was compared between the KS, ADC, and KS+ based on established high sensitivity thresholds (McNemar test).
RESULTS: A total of 450 lesions in 414 patients (mean age, 51.5 years; interquartile range, 42-60.8 years) were included, with 219 lesions being malignant (48.7%; 95% confidence interval [CI], 44%-53.4%). The performance of the KS (AUROC, 0.915; CI, 0.886-0.939) was significantly better than that of the ADC (AUROC, 0.848; CI, 0.811-0.880; P < 0.001). The largest difference between these parameters was observed when assessing subcentimeter lesions (AUROC, 0.909 for KS; CI, 0.849-0.950 vs 0.811 for ADC; CI, 0.737-0.871; P = 0.02).The use of the KS+ (AUROC, 0.918; CI, 0.889-0.942) improved the performance slightly, but without any significant difference relative to a single KS or ADC reading (P = 0.64).When applying high sensitivity thresholds for avoiding unnecessary biopsies, the KS and ADC achieved equal sensitivity (97.7% for both; cutoff values, >4 for KS and ≤1.4 × 10-3 mm2/s for ADC). However, the rate of potentially avoidable biopsies was higher when using the KS (specificity: 65.4% for KS vs 32.9% for ADC; P < 0.0001). The KS was superior to the KS+ in avoiding unnecessary biopsies.
CONCLUSIONS: Both the KS and ADC may be used to distinguish benign from malignant breast lesions. However, KS proved superior in this task including, most of all, when assessing small lesions less than 1 cm. Using the KS may avoid twice as many unnecessary biopsies, and the combination of both the KS and ADS does not improve diagnostic performance.
引用
- Dietzel M, Krug B, Clauser P, et al. A Multicentric Comparison of Apparent Diffusion Coefficient Mapping and the Kaiser Score in the Assessment of Breast Lesions. Invest Radiol. 2021. PMID: 33122603. doi:10.1097/RLI.0000000000000739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。